Discusses Recent and Upcoming Product Developments in Cancer Treatment
Montclair, N.J., July 8, 2013 (eTeligis vis ACCESSWIRE)– MetaStat, Inc. (MTST), a life science company focused on understanding and treating systemic metastasis, today announced that CEO Dr. Oscar Bronsther was recently interviewed on The Wall Street Analyst discussing the company’s diagnostic technologies and competitive positioning in the marketplace.
The Wall Street Analyst interviews CEOs and industry leaders to provide informative interviews that help investors understand companies, and make informed decisions on purchasing stock. Investors rely on The Wall Street Analyst to deliver unbiased, unfiltered, and candid interviews, which unlock possible investment opportunities before the rest of the market discovers them.
Interviewed by host Michael Noonan, Dr. Bronsther discusses MetaStat’s position in diagnosing and preventing metastatic cancer using the underlying biology of the tumor, which he expects, will help to provide the foundation for the company’s success. He also provides an update on the company’s recent developments, upcoming milestones, and the MenaBloc™ Therapeutic Platform.
To listen to the podcast, visit http://thewallstreetanalysts.com/metastat-inc-otcbbmtst-ceo-interview/
About MetaStat, Inc.
MetaStat is focused on developing and commercializing novel diagnostic technologies and therapeutics for the early and reliable prediction and treatment of systemic metastasis - cancer that spreads from a primary tumor through the bloodstream to other areas of the body. Systemic metastasis is responsible for ~90% of all solid tumor cancer related deaths and as such, we believe that more effective treatment of metastatic disease and/or the prevention of systemic metastasis is needed to improve patient outcomes.
Our MetaSite Breast™ and MenaCalc™ diagnostic product lines are designed to accurately predict the probability of systemic metastasis and to allow clinicians to better "customize" cancer treatment decisions by positively identifying patients with a high-risk of systemic metastasis who need aggressive therapy and by sparing patients with a low-risk of systemic metastasis from the harmful side effects and expense of chemotherapy. Furthermore, we believe our MenaCalc™ diagnostic platform may be applicable in up to 80% of all solid epithelial cancers, including breast, prostate, lung and colorectal, which account for over 50% of all new cancer cases in the U.S. each year.
Additionally, we are developing our MenaBloc™ therapeutic platform, with the goal of discovering inhibitors of the Mena pathway that can be advanced as anti-cancer therapeutics in multiple epithelial-based tumor types.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Adam Holdsworth, Managing Director
ProActive Capital Group, LLC
Sandra Lee, Managing Director
ProActive Capital Group, LLC
SOURCE: MetaStat, Inc.